...
alvo-img

Alvotech, Common Stock

ALVO

NMQ

$11.375

+$0.1

(0.89%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.45B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
57.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.15 L
$18 H
$11.375

About Alvotech, Common Stock

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALVOSectorS&P500
1-Week Return-3.26%-1.66%0.16%
1-Month Return-7.62%-3.08%1%
3-Month Return1.62%-6.66%10.69%
6-Month Return-21.99%-1.54%12.9%
1-Year Return23.68%8.85%30.94%
3-Year Return14.29%7.9%29.66%
5-Year Return15.69%45.12%92.82%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue31.92M66.62M36.77M83.03M91.43M[{"date":"2019-12-31","value":34.91,"profit":true},{"date":"2020-12-31","value":72.86,"profit":true},{"date":"2021-12-31","value":40.22,"profit":true},{"date":"2022-12-31","value":90.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue---64.09M160.86M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":39.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit31.92M66.62M36.77M18.93M(69.42M)[{"date":"2019-12-31","value":47.91,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":55.2,"profit":true},{"date":"2022-12-31","value":28.42,"profit":true},{"date":"2023-12-31","value":-104.21,"profit":false}]
Gross Margin100.00%100.00%100.00%22.80%(75.93%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.8,"profit":true},{"date":"2023-12-31","value":-75.93,"profit":false}]
Operating Expenses93.37M204.15M272.23M365.38M285.44M[{"date":"2019-12-31","value":25.55,"profit":true},{"date":"2020-12-31","value":55.87,"profit":true},{"date":"2021-12-31","value":74.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.12,"profit":true}]
Operating Income(61.45M)(137.54M)(235.46M)(346.44M)(354.86M)[{"date":"2019-12-31","value":-6144800000,"profit":false},{"date":"2020-12-31","value":-13753700000,"profit":false},{"date":"2021-12-31","value":-23545600000,"profit":false},{"date":"2022-12-31","value":-34644200000,"profit":false},{"date":"2023-12-31","value":-35486000000,"profit":false}]
Total Non-Operating Income/Expense(244.77M)(254.75M)(28.28M)(295.73M)(426.19M)[{"date":"2019-12-31","value":-24477200000,"profit":false},{"date":"2020-12-31","value":-25474600000,"profit":false},{"date":"2021-12-31","value":-2828000000,"profit":false},{"date":"2022-12-31","value":-29573100000,"profit":false},{"date":"2023-12-31","value":-42619000000,"profit":false}]
Pre-Tax Income(209.38M)(291.77M)(149.20M)(551.65M)(651.05M)[{"date":"2019-12-31","value":-20938500000,"profit":false},{"date":"2020-12-31","value":-29177000000,"profit":false},{"date":"2021-12-31","value":-14919800000,"profit":false},{"date":"2022-12-31","value":-55164700000,"profit":false},{"date":"2023-12-31","value":-65104900000,"profit":false}]
Income Taxes491.00K(121.73M)(47.69M)(38.07M)(99.32M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-24791.45,"profit":false},{"date":"2021-12-31","value":-9713.65,"profit":false},{"date":"2022-12-31","value":-7752.95,"profit":false},{"date":"2023-12-31","value":-20227.7,"profit":false}]
Income After Taxes(209.88M)(170.04M)(101.50M)(513.58M)(551.73M)[{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}]
Income From Continuous Operations(209.88M)(170.04M)(101.50M)(513.58M)(551.73M)[{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(209.88M)(170.04M)(101.50M)(513.58M)(551.73M)[{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}]
EPS (Diluted)-(0.30)0.13(5.53)(3.42)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-231.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4330.67,"profit":false},{"date":"2023-12-31","value":-2676.06,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALVO
Cash Ratio 0.74
Current Ratio 2.69
Quick Ratio 1.92

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALVO
ROA (LTM) -7.61%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALVO
Debt Ratio Lower is generally better. Negative is bad. 1.28
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.28

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALVO
Trailing PE NM
Forward PE NM
P/S (TTM) 11.16
P/B 0.00
Price/FCF NM
EV/R 11.50
EV/Ebitda NM

FAQs

What is Alvotech share price today?

Alvotech (ALVO) share price today is $11.375

Can Indians buy Alvotech shares?

Yes, Indians can buy shares of Alvotech (ALVO) on Vested. To buy Alvotech from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alvotech be purchased?

Yes, you can purchase fractional shares of Alvotech (ALVO) via the Vested app. You can start investing in Alvotech (ALVO) with a minimum investment of $1.

How to invest in Alvotech shares from India?

You can invest in shares of Alvotech (ALVO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALVO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alvotech shares
What is Alvotech 52-week high and low stock price?

The 52-week high price of Alvotech (ALVO) is $18. The 52-week low price of Alvotech (ALVO) is $9.15.

What is Alvotech price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Alvotech (ALVO) is

What is Alvotech price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alvotech (ALVO) is 0.00

What is Alvotech dividend yield?

The dividend yield of Alvotech (ALVO) is 0.00%

What is the Market Cap of Alvotech?

The market capitalization of Alvotech (ALVO) is $3.45B

What is Alvotech’s stock symbol?

The stock symbol (or ticker) of Alvotech is ALVO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top